Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.53 +0.88 (+5.29%)

Streaming Delayed Price Updated: 3:53 PM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

From Novocure

Via Business Wire

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

December 01, 2025

From Novocure

Via Business Wire

NovoCure (NVCR) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

NovoCure (NVCR) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

November 26, 2025

From Novocure

Via Business Wire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For July 24, 2025 ↗

July 24, 2025

Via Benzinga

NovoCure Earnings Preview ↗

July 23, 2025

Via Benzinga

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon ↗

November 12, 2025

If you have decades of investing runway left, consider these two top healthcare stocks.

Via The Motley Fool

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

November 12, 2025

From Novocure

Via Business Wire

Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher ↗

October 30, 2025

Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers.

Via Chartmill

Novocure Reports Third Quarter 2025 Financial Results

October 30, 2025

From Novocure

Via Business Wire

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

October 15, 2025

From Novocure

Via Business Wire

Novocure to Report Third Quarter 2025 Financial Results

October 01, 2025

From Novocure

Via Business Wire

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

September 29, 2025

From Novocure

Via Business Wire

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

September 15, 2025

From Novocure

Via Business Wire

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗

August 29, 2025

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

Via The Motley Fool

Novocure Announces Upcoming Investor Events

August 28, 2025

From Novocure

Via Business Wire

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

August 25, 2025

From Novocure

Via Business Wire

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20, 2025

From Novocure

Via Business Wire

Top 3 Health Care Stocks That May Explode In July ↗

July 28, 2025

Via Benzinga

NovoCure Q2 Revenue Jumps 6 Percent ↗

July 24, 2025

Via The Motley Fool

Topics World Trade

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 24, 2025

Via Benzinga

Novocure: Steady Ahead of Key Milestones ↗

July 24, 2025

Via The Motley Fool

Novocure Reports Second Quarter 2025 Financial Results

July 24, 2025

From Novocure

Via Business Wire

This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday ↗

July 08, 2025

Via Benzinga

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

July 01, 2025

From Novocure

Via Business Wire

Novocure to Report Second Quarter 2025 Financial Results

June 30, 2025

From Novocure

Via Business Wire

Demystifying NovoCure: Insights From 4 Analyst Reviews ↗

June 27, 2025

Via Benzinga

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial ↗

June 02, 2025

TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.